{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-006056","form_type":"8-K","ticker":"CLDX","cik":"0000744218","company_name":"Celldex Therapeutics, Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.959105+00:00","generated_at":"2026-05-30T04:57:07.684183+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Celldex Q3 net loss $42.1M; barzolvolimab meets Phase 2 CIndU endpoints","bullets":["Net loss of $42.1M ($0.64 per share) vs $38.3M in Q3 2023; revenue $3.2M vs $1.5M.","Cash $756.0M as of Sep 30, 2024, down from $802.3M; expects to fund operations through 2027.","Barzolvolimab met all primary/secondary endpoints in Phase 2 CIndU; up to 57.6% complete response in SD.","Global Phase 3 CSU trials (EMBARQ-CSU1/2) actively enrolling; CIndU Phase 3 planned for 2025.","First bispecific CDX-622 (SCF/TSLP) entering Phase 1 in Q4 2024; CDX-585 development halted."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-006056","json":"https://secwatch.observer/filing/0001171843-24-006056.json","markdown":"https://secwatch.observer/filing/0001171843-24-006056.md","text":"https://secwatch.observer/filing/0001171843-24-006056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744218/000117184324006056/0001171843-24-006056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744218/000117184324006056/f8k_110624.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:57:07.684183+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}